GSK To Get $370 Mln Upfront Payment From CureVac With MRNA Patent Settlement

GSK plc will receive an upfront $370 million ($320 million cash) from CureVac via an mRNA patent settlement, which also grants GSK a 1% royalty on US sales of BioNTech/Pfizer's influenza/COVID-19 mRNA vaccines from 2025 and significantly reduces GSK's own future mRNA product royalties. The agreement, which includes GSK tendering its CureVac shares, offers an additional $130 million and international royalties contingent on BioNTech's acquisition of CureVac, effectively monetizing GSK's intellectual property and enhancing its mRNA pipeline's profitability while notably preserving its ongoing patent litigation against Pfizer and BioNTech.

Analysis

GSK plc has successfully monetized its intellectual property through a patent settlement with CureVac, securing a $370 million upfront payment, of which $320 million is in cash. This agreement establishes a new, recurring revenue stream for GSK, granting it a 1% royalty on US sales of BioNTech and Pfizer's mRNA influenza and COVID-19 combination vaccines beginning in 2025. Critically, the deal also enhances the future profitability of GSK's own mRNA pipeline by significantly reducing the royalties it will have to pay on its potential vaccine products. Further upside is contingent upon the successful acquisition of CureVac by BioNTech, which would trigger an additional $130 million payment to GSK and expand the 1% royalty to ex-US sales. Importantly, this resolution does not impact GSK's separate and ongoing patent infringement litigation against Pfizer and BioNTech, allowing the company to realize immediate value from its CureVac license while preserving the potential for a larger, direct legal victory.

Key Decisions for Investors

• The settlement provides GSK with a non-dilutive cash infusion and a durable new royalty stream, strengthening the company's financial position and validating its intellectual property portfolio.
• Investors should monitor the progress of the BioNTech-CureVac acquisition as a near-term catalyst for additional payments, while recognizing that GSK's separate, direct litigation against Pfizer/BioNTech remains a key, unresolved factor with potentially greater financial implications.
• The reduction in future royalty payments on GSK's own mRNA products improves the long-term margin profile of its vaccine pipeline, enhancing its competitive standing against key rivals.